DalsnaFinance

HERVolution Therapeutics Presents Clinical Evidence of HERV-K Driving Metabolic Senescence at the International Congress on Obesity 2026

Markets PR Newswire By PR Newswire 15 Jul 2026 10:00 1 min read
HERVolution Therapeutics Presents Clinical Evidence of HERV-K Driving Metabolic Senescence at the International Congress on Obesity 2026

Findings demonstrate HERV-K is required for senescence-associated inflammation in metabolically challenged cells and is reactivated in plasma of subjects living with obesity COPENHAGEN, Denmark and NEW YORK, July 15, 2026 /PRNewswire/ -- HERVolution Therapeutics ApS, a biotechnology...

Findings demonstrate HERV-K is required for senescence-associated inflammation in metabolically challenged cells and is reactivated in plasma of subjects living with obesity COPENHAGEN, Denmark and NEW YORK, July 15, 2026 /PRNewswire/ -- HERVolution Therapeutics ApS, a biotechnology...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.